https://scholars.lib.ntu.edu.tw/handle/123456789/617820
標題: | Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant) | 作者: | Wu, Jia-Jun Lee, Po-Hsin Zheng, Zhe-Rong Huang, Yen-Hsiang Tseng, Jeng-Sen Hsu, Kuo-Hsuan Yang, Tsung-Ying SUNG-LIANG YU Chen, Kun-Chieh Chang, Gee-Chen |
關鍵字: | immune checkpoint inhibitor; Kirsten rat sarcoma; lung cancer; never-smoker; programmed death-ligand 1; SMOKING; IMPACT; EGFR; FREQUENCY; EFFICACY; SUBTYPE; ROS1 | 公開日期: | 17-六月-2022 | 出版社: | LIPPINCOTT WILLIAMS & WILKINS | 卷: | 101 | 期: | 24 | 來源出版物: | Medicine | 摘要: | Kirsten rat sarcoma (KRAS) mutation (KRASm) is associated with poor prognosis in non-small cell lung cancer (NSCLC) patients. We have aimed to survey NSCLC patients harboring KRASm in Taiwan, where never-smoking lung adenocarcinoma predominates, and analyze the immune checkpoint inhibitor effect on NSCLC harboring KRASm.NSCLC patients with KRASm were enrolled and tested on programmed death-ligand 1 (PD-L1) expression using available tissue. We analyzed their clinical features, PD-L1 status, responses to ICIs, and overall survival (OS).We studied 93 patients with a median age 66.0 years, 23.7% of whom were women, and 22.6% were never-smokers. The results showed that G12C (36.6%) was the most common KRASm. In 47 patients with available tissue for PD-L1 testing, PD-L1 expression was positive in 66.0% of patients, while PD-L1 ≥50% was higher in ever-smokers (P = .038). Among 23 patients receiving ICI treatment, those with PD-L1 ≥50% experience a 45.5% response rate to ICI. There were benefits from ICI treatment on OS compared with no ICI treatment (median OS 35.6 vs 9.8 months, P = .002) for all of our patients, and for patients with PD-L1 ≥50% (median OS not-reached vs 8.4 months, P = .008). There were no differences in survival across different KRAS subtypes (P = .666).Never-smokers composed more than one-fifth of KRASm in NSCLC in Taiwan. A high PD-L1 expression was related to smoking history and responded well to ICI. ICI treatment improved the OS in NSCLC patients with KRASm, particularly those with PD-L1 ≥50%. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/617820 | ISSN: | 0025-7974 | DOI: | 10.1097/MD.0000000000029381 |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。